La vendita allo scoperto per Enovix dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Enovix. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Enovix (NASDAQ:ENVX) Azioni, Report sulle vendite allo scoperto

ENOVIX CORP

Enovix

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

Enovix Corp

UBS analyst Steven Fisher downgrades Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) from Buy to Neutral and lowers the price target from $343 to $258.

News

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Vulcan Materials to Neutral, Lowers Price Target to $258

UBS analyst Steven Fisher maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Neutral and lowers the price target from $269 to $234.

UBS Maintains Neutral on Illinois Tool Works, Lowers Price Target to $234

UBS analyst Steven Fisher downgrades United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from Neutral to Sell and lowers the price target from $910 to $485.

UBS Downgrades United Rentals to Sell, Lowers Price Target to $485

WIIM

SMHI

SEACOR Marine Holdings shares are trading higher after the company announced a $12.9 million repurchase of shares and warrants from Carlyle.

ARES

Shares of some banking and financial services stocks are trading higher as markets rebound following earlier weakness.

UBS analyst Steven Fisher downgrades Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) from Buy to Sell and lowers the price target from $400 to $240.

UBS Downgrades Cummins to Sell, Lowers Price Target to $240

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) has officially wandered into Wall Street's technical &#8220;danger zone.&#8221; A <a href="https://www.benzinga.com/topic/death-cross">dreaded Death Cross</a> has formed—when the 50-day moving average dips below the 200-day average—signaling a potentially bearish path ahead.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407"><img loading="lazy" decoding="async" width="629" height="491" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07135649/Screenshot-2025-04-07-at-11.24.01-PM.png" alt="" class="wp-image-860517" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07135649/Screenshot-2025-04-07-at-11.24.01-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07135649/Screenshot-2025-04-07-at-11.24.01-PM-300x234.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
But if you think this is game over for GameStop, think again.
Despite the grim chart pattern, CEO Ryan Cohen appears unfazed. Just last week, <a href="https://www.benzinga.com//node/44638041">he snapped up</a> 500,000 more shares, boosting his stake to 8.4%. 
That vote of confidence sent GME stock soaring 11% to $23.49, even as the broader market slumped.
Read Also: <a href="https://www.benzinga.com//node/44531398">Peter Schiff Slams Gamestop&#8217;s Bitcoin Strategy As Shares Plummet: &#8216;Now That All The Fools Have Already Rushed In, Smarter Investors Are Selling&#8217;</a>
<h2 class="wp-block-heading">Bearish Signs Everywhere &#8211; Except One</h2>
Technically, GME stock is looking rough. It's trading below its five, 20, 50 and 200-day exponential and simple moving averages. The MACD (moving average convergence/divergence) indicator is in negative territory, and the RSI (relative strength index) hovers at a neutral 51.58 &#8211; no clear momentum, just drifting.
Analysts call this setup &#8216;strongly bearish,&#8217; yet there's buying pressure. Enough, perhaps, to fuel a short-term bounce.
<h2 class="wp-block-heading">Bitcoin, Bonds, Bold Moves</h2>
Cohen's share grab followed <a href="https://colitco.com/gamestop-bitcoin-investment-convertible-bond-sale/">news</a> that GameStop has added Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to its corporate investment strategy and plans to raise $1.3 billion via convertible bonds to fund that venture.
Investors initially cheered the crypto pivot, only to balk at the bond offering, sending the stock plunging by 25% before Friday's rebound.
With GME forming a Death Cross, bears may feel vindicated. But as Cohen doubles down and meme stock momentum stirs, traders might want to think twice before calling it quits. 
GameStop has a habit of turning chaos into opportunity, and right now, all eyes are on whether it can pull this off again.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/44643100">Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was &#8216;100% Smoot Hawley Disguised As Thoughtful Policy,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Gaming

Technicals

Markets

Tech

Trading Ideas

General

$BTC

GameStop Enters The Danger Zone: Death Cross Flashes, But Ryan Cohen Isn't Flinching

Shares of the Health Care Select Sector SPDR Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NASDAQ">XLV</a>) are trading lower by 8.6% to $132.86 over the past week as tariff announcements from President Donald Trump last week spooked investors and <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">dragged major sectors</a> of the market lower. 
While healthcare is often viewed as a defensive play during times of uncertainty, the <a href="https://www.benzinga.com/general/health-care">sector</a> is not immune to the broader economic implications of escalating trade tensions.
<h2 class="wp-block-heading">What Is XLV?</h2>
The Health Care Select Sector SPDR Fund is an exchange-traded fund that tracks the performance of the Health Care Select Sector Index, which includes large U.S. healthcare companies across pharmaceuticals, biotechnology, healthcare equipment and managed care. Top holdings include Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) .
Although healthcare demand tends to be less cyclical than sectors like industrials or energy, many of XLV's components are <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">exposed to global markets</a>, supply chains and regulatory dynamics—all of which can be disrupted by a trade war.
Read Also: <a href="https://www.benzinga.com/news/25/04/44670684/whats-going-on-with-financial-select-sector-spdr-fund-xlf">What&#8217;s Going On With Financial Select Sector SPDR Fund (XLF)?</a>
<h2 class="wp-block-heading">Why Are Tariffs Hitting Healthcare—and XLV?</h2>
At first glance, healthcare might seem like an unlikely victim of tariff tensions, but the industry is more globally interconnected than it appears. Here's how tariff escalation is weighing on XLV and its underlying holdings:
<ul>
<li>Global Supply Chain Disruptions: Many medical devices and pharmaceutical ingredients are manufactured or sourced overseas. Tariffs on imported materials from countries like China can increase production costs for companies like Medtronic and Abbott Laboratories, which rely on <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">international supply chains</a> to maintain margins and deliver products at scale. </li>
<li>Pricing Pressures Intensify: Healthcare companies already face intense political scrutiny over pricing. Tariffs add another <a href="https://www.benzinga.com/news/global/25/04/44668830/we-want-fairness-white-house-trade-adviser-navarro-says-trump-administration-is-focused-on-non-tariff-cheating">layer of cost inflation</a> that may be difficult to pass along to consumers or insurers. That's especially challenging for drugmakers and device manufacturers that operate under tight pricing regulations or depend on long-term contracts. </li>
<li>Global Growth Matters: Multinational pharmaceutical companies such as Pfizer and Johnson &amp; Johnson derive a significant share of their revenue from international markets. A slowdown in global economic growth due to <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">trade tensions</a> can dampen demand for branded drugs and medical products abroad, squeezing top-line growth. </li>
<li>Market Volatility Hits Sentiment: Even though healthcare is traditionally considered defensive, the sector is still susceptible to broader market moves. Investors often rotate out of equities—including healthcare—during times of heightened uncertainty. Additionally, biotech and life sciences stocks, many of which are included in XLV, tend to be more volatile and sensitive to shifts in investor risk appetite.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What&#8217;s Driving Markets Monday?</a>

Why Health Care Select Sector SPDR Fund (XLV) Is Moving

UBS analyst Thomas Wadewitz maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Neutral and lowers the price target from $61 to $45.

ALGT

UBS Maintains Neutral on Allegiant Travel, Lowers Price Target to $45

<a href="https://www.wsj.com/tech/apple-iphone-production-china-tariffs-6cc37f40?mod=tech_lead_story" title="https://www.wsj.com/tech/apple-iphone-production-china-tariffs-6cc37f40?mod=tech_lead_story">https://www.wsj.com/tech/apple-iphone-production-china-tariffs-6cc37f40?mod=tech_lead_story</a>

AAPL

'Apple Plans to Source More iPhones From India as Potential Tariff Fix' -Wall Street Journal Report

UBS analyst Atul Maheswari maintains Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) with a Neutral and lowers the price target from $7 to $4.

ULCC

UBS Maintains Neutral on Frontier Group Holdings, Lowers Price Target to $4

UBS analyst Thomas Wadewitz maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Sell and lowers the price target from $5 to $3.

JBLU

UBS Maintains Sell on JetBlue Airways, Lowers Price Target to $3

ANRO

Alto Neuroscience shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $10 price target.

UBS analyst Thomas Wadewitz maintains Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Neutral and lowers the price target from $36 to $27.

UBS Maintains Neutral on Southwest Airlines, Lowers Price Target to $27

XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) joined the broader crypto sell-off on Monday, tumbling 10% and sparking a <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44664914/bitcoin-ethereum-xrp-dogecoin-obliterate-142-billion-in-liquidations-plummet-up-to-16">wave of liquidations</a>. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$1.88</td>
<td>$110.05 billion</td>
<td>-8%&nbsp;</td>
<td>-10.5%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$78,338.92</td>
<td>$1.55 trillion</td>
<td>-3.8%&nbsp;</td>
<td>-6%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$1,552.22</td>
<td>$187.3 billion</td>
<td>-8.6%&nbsp;</td>
<td>-15.7%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Oscar Ramos <a href="https://x.com/realOscarRamos1/status/1909243845893562745">shared</a> his take on the current market chaos, noting he picked up XRP at $1.69 following its plunge to an intraday low of $1.61 — just before a modest bounce to $1.80. 
Though XRP remains under pressure and has lost key support near $2, Ramos said, "I bought the dip — not the mega dip at $1.61, but at least I got $1.69."
He also flagged broader macro headwinds, citing the NASDAQ opening under 15,000.
Speculation is swirling over the possibility of an emergency rate cut to counter accelerating market declines. Ramos posed the question many are asking: &#8220;Can the Fed do an emergency cut to slow the pain of the crashing in the world right now?&#8221;
Statistics: XRP's sharp drop pushed long liquidations to $41.1 million in the past 24 hours — the highest since March 3, 2025, according to Coinglass data. Short liquidations also surged to $19.32 million, marking the highest level since March 2.
XRP derivatives trading volume exploded by 587% in the same period, highlighting the heightened activity amid extreme volatility.
Whale Alert data <a href="https://x.com/whale_alert/status/1909182445431271932">shows</a> that 200 million XRP—valued at $355.6 million—was moved from an unknown wallet to Binance, sparking speculation that whales might have insider knowledge the broader market lacks.
Community News: Despite short-term price pressure, Ripple's latest <a href="https://ripple.com/ripple-press/global-financial-infrastructure-entering-a-new-era/">report</a> predicts strong long-term fundamentals for XRP. It forecasts that the tokenized real-world asset market could grow from $0.6 trillion today to $9.4 trillion by 2030 — and even hit $18.9 trillion by 2033.
The projected 53% CAGR will be driven by XRP and Ripple's stablecoin RLUSD, with growth unfolding in three key stages: low-risk adoption, institutional expansion and full market transformation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44647456/bitcoin-xrp-diversion">Bitcoin Consolidates, But XRP May Have Topped: What&#8217;s Driving This Diversion?</a></li>
</ul>
Image: Shutterstock

$ETH

$XRP

XRP Down 10% In A Single Day: Is The Worst Over?

UBS analyst Thomas Wadewitz maintains American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Neutral and lowers the price target from $13 to $9.

UBS Maintains Neutral on American Airlines Group, Lowers Price Target to $9

HC Wainwright initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), a commercial-stage biotech company focused on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">RNA-targeted therapeutics</a>.
Analyst Mitchell Kapoor says Ionis has used its RNA technology to develop a wide range of drugs. The analyst believes Ionis has built a strong and valuable platform with drug opportunities that carry less risk thanks to its track record of success in clinical trials, regulatory approvals, and commercial launches over the next few years, all supported by strong cash flow.
In addition to its major programs, Kapoor highlights Ionis&#8217; promising early-stage projects in the pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44276870/ionis-pharmaceuticals-partners-with-japan-based-ono-pharmaceutical-for-rare-blood-disease-drug-in-over-800-million-deal" rel="noreferrer noopener">Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal</a>
&#8220;The company's pipeline depth has allowed for constant business development to support the growth of the company as well as continued research and development,&#8221; Kapoor writes.
HC Wainwright initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/IONS/analyst-ratings" rel="noreferrer noopener">price target of $45</a>.
Ionis already has several approved drugs. The spotlight is now shifting to new product launches and important clinical trial results expected in 2025 and 2026. Two drugs worth noting:
<ul>
<li><a href="https://www.benzinga.com/24/12/42613640/fda-approves-ionis-pharmaceuticals-rare-genetic-disease-therapy-to-lower-high-level-of-fat-in-blood" target="_blank" rel="noreferrer noopener">Tryngolza (olezarsen)</a>, aimed at lowering triglycerides. Two major Phase 3 trial results are expected in the second half of 2025 for treating severe hypertriglyceridemia (sHTG). These results are seen as a key growth opportunity. Analyst Kapoor adds that if successful, and if the drug is approved for sHTG, Ionis would fully control U.S. sales and have strong international rights as well. The U.S. market alone includes about 2.3 million patients.</li>
<li>Wainua (eplontersen), used to treat transthyretin-mediated amyloidosis (ATTR).</li>
</ul>
HC Wainwright sees potential FDA approval (PDUFA date of Aug. 21) for donidalorsen in hereditary angioedema (HAE) as a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39118220/ionis-pharmaceuticals-reveals-late-stage-donidalorsen-data-analyst-says-results-sho" target="_blank" rel="noreferrer noopener">near-term stock driver</a>.
&#8220;We think the market does not fully appreciate the potential for differentiation, given a far less-frequent dosing regimen for donidalorsen vs. SOC,&#8221; the analyst writes.
Ionis said 2024 revenue of $705 million exceeded guidance as the company continued to generate revenue from diverse sources. The company added new revenue sources in 2024 with the launch of Wainua and Tryngolza <a href="https://www.benzinga.com/25/02/43818962/ionis-pharmaceuticals-says-2024-revenue-exceeds-guidance-on-sales-from-diverse-sources-forecasts-over-600-million-in-2025-sales">in the U.S.</a>
Price Action: IONS stock is down 0.33% at $27 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44670067/anavex-life-sciences-long-term-trial-data-for-blarcamesine-treatment-slows-cognitive-and-functional-decline-in-alzheimers-patients" target="_blank" rel="noreferrer noopener">Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer&#8217;s Over 3 Years</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

Initiation

IONS

Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'

UBS analyst Steven Fisher downgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Neutral to Sell and lowers the price target from $385 to $243.

UBS Downgrades Caterpillar to Sell, Lowers Price Target to $243

AMAT

INDI

KLAC

LRCX

MCHP

NVDA

SMCI

TSEM

Shares of chip stocks are trading higher amid overall market volatility. Stocks across sectors have been volatile on Monday, with tech stocks rebounding following earlier weakness.

Comments

Enovix

Vendite allo scoperto

Enovix (NASDAQ:ENVX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO